Payment overview · 2025
General Payments
$381.22
20 reported records · 9 companies
Healthcare provider profile · identity verified
Hugh T Stoddard, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SUMTER, SC · NPI 1497743595
Verified facts
What the public records show
CMS Open Payments records show Hugh T Stoddard, MD received $381.22 in general payments during 2025 across 20 reported records.
Novo Nordisk Inc accounted for 41.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $159.82 | 41.9% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $84.47 | 22.2% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $27.34 | 7.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.43 | 6.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.70 | 5.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.39 | 5.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.23 | 4.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.03 | 3.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.81 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $381.22 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $159.82 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $80.84 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $66.64 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $66.64 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $27.34 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 59 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
205 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 323 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 304 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 239 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 216 | 44 |
| Losartan Potassium | Losartan Potassium | 215 | 59 |
| Omeprazole | Omeprazole | 206 | 53 |
| Eliquis | Apixaban | 205 | 28 |
| Lorazepam | Lorazepam | 198 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 187 | 56 |
| Alprazolam | Alprazolam | 153 | 27 |
| Gabapentin | Gabapentin | 147 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 146 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 35 |
| Furosemide | Furosemide | 130 | 33 |
| Sertraline Hcl | Sertraline Hcl | 125 | 28 |
| Carvedilol | Carvedilol | 122 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 118 | 16 |
| Famotidine | Famotidine | 117 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 31 |
| Prednisone | Prednisone | 102 | 41 |
| Clonazepam | Clonazepam | 98 | 14 |
| Estradiol | Estradiol | 95 | 17 |
| Tramadol Hcl | Tramadol Hcl | 95 | 18 |
| Allopurinol | Allopurinol | 86 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 27 |
| Lisinopril | Lisinopril | 79 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 79 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 73 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 18 |
| Ezetimibe | Ezetimibe | 67 | 16 |
| Potassium Chloride | Potassium Chloride | 67 | 19 |
| Cephalexin | Cephalexin | 66 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 64 | 12 |
| Metformin Hcl Er | Metformin Hcl | 63 | 18 |
| Trazodone Hcl | Trazodone Hcl | 63 | 15 |
| Montelukast Sodium | Montelukast Sodium | 62 | 21 |
| Testosterone Cypionate | Testosterone Cypionate | 61 | suppressed |
| Jardiance | Empagliflozin | 59 | 12 |
| Diazepam | Diazepam | 55 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 14 |
| Metformin Hcl | Metformin Hcl | 55 | 14 |
| Memantine Hcl | Memantine Hcl | 54 | suppressed |
| Simvastatin | Simvastatin | 54 | 15 |
| Azithromycin | Azithromycin | 53 | 33 |
| Spironolactone | Spironolactone | 52 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 13 |
| Donepezil Hcl | Donepezil Hcl | 50 | 12 |
| Finasteride | Finasteride | 50 | 11 |
| Meloxicam | Meloxicam | 49 | 12 |
| Fluconazole | Fluconazole | 48 | 22 |
| Glimepiride | Glimepiride | 48 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | suppressed |
| Pregabalin | Pregabalin | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | 13 |
| Colchicine | Colchicine | 43 | 15 |
| Glipizide Er | Glipizide | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 12 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Telmisartan | Telmisartan | 33 | 11 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Cefdinir | Cefdinir | 30 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 14 |
| Temazepam | Temazepam | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | 13 |
| Amoxicillin | Amoxicillin | 27 | 20 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | suppressed |
| Carisoprodol | Carisoprodol | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Premarin | Estrogens, Conjugated | 25 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 20 | 15 |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Estazolam | Estazolam | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Triazolam | Triazolam | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Restasis Multidose | Cyclosporine | 12 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $381.22 · 20 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, EVENITY, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Korlym, Leqembi, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error